Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 6/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18431417 | 0.94 | TLR8 (0.43) | TLR8NUDT1TLR7HRH3HRH4 | |
| SCHEMBL20049876 | 0.91 | TLR8 (0.43) | TLR8NUDT1TLR7HRH3HRH4 | |
| SCHEMBL19618116 | 0.91 | TLR8 (0.45) | TLR8NUDT1TLR7HRH3HRH4 | |
| SCHEMBL22065925 | 0.80 | TLR8 (0.32) | TLR8TLR7 | |
| SCHEMBL25466603 | 0.79 | TLR8 (0.34) | TLR8TLR7 | |
| SCHEMBL26850422 | 0.77 | KCNH2 (0.34) | TLR8TLR7 | |
| SCHEMBL21719187 | 0.75 | KCNH2 (0.32) | TLR8TLR7 | |
| SCHEMBL21719076 | 0.74 | AR (0.32) | TLR8TLR7 | |
| SCHEMBL21719179 | 0.74 | TLR8 (0.30) | TLR8TLR7 | |
| SCHEMBL21719183 | 0.74 | TLR8 (0.30) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360795-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | TLR8 4679/4885NUDT1 1478/4885TLR7 4114/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | TLR8 4679/4885NUDT1 1478/4885TLR7 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.